CNC
Centene CorporationNYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Today, 7:30 AM
    • Philip van Doorn and team at Marketwatch put together a list of 18 S&P 500 names with consensus sell-side price targets at least 30% above the current price.
    • Ten of the 18 stocks are in healthcare, which has been roughed up by a combination of Obamacare, Clinton's talk about drug pricing (back when all thought she would be the next POTUS), and now Trump joining in the bashing.
    • The list (in order of possible upside): Mallinckrodt PLC (NYSE:MNK) - 56% potential upside, Endo International PLC (NASDAQ:ENDP) - 52% upside, Hanesbrands (NYSE:HBI) - 45% upside, Edwards Lifesciences (NYSE:EW) - 44% upside, Mylan (NASDAQ:MYL) - 42% upside, Allergan (NYSE:AGN) - 39% upside, Alexion (NASDAQ:ALXN) - 37% upside, Activision Blizzard (NASDAQ:ATVI) - 35% upside, Salesforce.com (NYSE:CRM) 34% upside, NRG Energy (NYSE:NRG) - 34% upside, Centene (NYSE:CNC) 34% upside, Gilead (NASDAQ:GILD) 33% upside, Facebook (NASDAQ:FB) 32% upside, Boston Scientific (NYSE:BSX) - 32% upside, Pitney owes (NYSE:PBI) - 32% upside, Molson Coors (NYSE:TAP) - 30% upside, Newell Brands (NYSE:NWL) - 30% upside, Zimmer Bioment (NYSE:ZBH) - 30% upside.
    | Today, 7:30 AM | 25 Comments
  • Tue, Dec. 6, 8:03 AM
    • Tenet Healthcare (NYSE:THC) and Centene (NYSE:CNC) sign a new three-year agreement providing Centene and Health Net members in-network access to Tenet's hospitals, outpatient centers and employed physicians in 18 states. The new contract integrates all of Centene's and Health Net's insurance products into a single agreement following Centene's acquisition of Health Net earlier this year.
    • The contract will go into effect January 1.
    | Tue, Dec. 6, 8:03 AM
  • Wed, Nov. 9, 12:42 PM
    | Wed, Nov. 9, 12:42 PM
  • Wed, Nov. 9, 11:06 AM
    | Wed, Nov. 9, 11:06 AM | 5 Comments
  • Wed, Nov. 9, 3:03 AM
    • Healthcare stocks, the weakest sector this year, may become winners, as Obamacare reforms are set to be "repealed and replaced" and major legislation Clinton proposed is unlikely to be imposed on drugmakers.
    • While Trump hasn't set out a comprehensive alternative to the Affordable Care Act (which may see 22M Americans lose current coverage), he said he'll encourage competition between markets in different states.
    • Insurance stocks: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    • Drugmakers premarket: MYL +5.8%, NVS +3.4%, SNY +2.9%, AZN +2.4%, GSK +1.9%, PFE +1.8%, CELG +1%, ABBV, MRK, BMY, LLY, JNJ, ABT, ACET, ZTS, BIIB, REGN
    • #Election2016
    | Wed, Nov. 9, 3:03 AM | 14 Comments
  • Thu, Oct. 27, 3:41 AM
    • Not only are Obamacare premiums on the rise for 2017, deductibles will also be getting more expensive, according to an analysis by insurance comparison site HealthPocket.
    • Deductibles for individuals enrolled in the lowest-priced Obamacare health plans will average more than $6,000 next year, the first time that threshold has been cracked in the three years that Affordable Care Act marketplaces have been in business. Families enrolled in the bronze plans will average deductibles of $12,393.
    • Previously: Obamacare rates up 25% in 2017 (Oct. 25 2016)
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    | Thu, Oct. 27, 3:41 AM | 42 Comments
  • Tue, Oct. 25, 8:30 AM
    • Centene (NYSE:CNC) Q3 results ($M): Total Revenues: 10,846 (+86.3%); Premium: 9,625 (+93.2%); Service: 590 (+22.9%); Premium Tax and Health Insurer Fee: 631 (+76.3%);
    • Net Income: 145 (+55.9%); EPS: 0.84 (+12.0%); Non-GAAP EPS: 1.11 (+27.6%); CF Ops: 255 (9 mo.): 255 (-44.2%);
    • Operating Expenses: 10,504 (+86.3%); Medical Costs: 8,376 (+88.9%); Health Benefits Ratio: 87.0% (-2.2%).
    • 2016 Guidance: Total Revenues: $39.4B - 40.0B (unch); EPS: $2.73 - 2.83 from $2.65 - 3.00; Non-GAAP EPS: 4.28 - 4.38 from $4.20 - 4.55.
    • Q4 Guidance: EPS: $0.83 - 0.93; Non-GAAP EPS: $1.05 - 1.15.
    | Tue, Oct. 25, 8:30 AM
  • Tue, Oct. 25, 6:06 AM
    • Centene (NYSE:CNC): Q3 EPS of $1.16 in-line.
    • Revenue of $10.85B (+86.4% Y/Y) misses by $110M.
    • Shares +0.08% PM.
    • Press Release
    | Tue, Oct. 25, 6:06 AM | 1 Comment
  • Tue, Oct. 25, 2:22 AM
    • The average premium for benchmark 2017 Obamacare insurance plans sold on Healthcare.gov will jump 25% to $302 compared to this year, the biggest increase since the insurance first went on sale in 2013.
    • Seeking to downplay the cost hikes, the administration said that including subsidies 77% of people would be able to find insurance plans with monthly premiums below $100, however, one in five consumers will only have one insurer from which to choose coverage.
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    | Tue, Oct. 25, 2:22 AM | 43 Comments
  • Mon, Oct. 24, 5:30 PM
    | Mon, Oct. 24, 5:30 PM | 28 Comments
  • Fri, Sep. 9, 9:59 AM
    • Eli Lilly (NYSE:LLY) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $95 (20% upside) from $92.
    • Ligand Pharmaceuticals (NASDAQ:LGND) upgraded to Hold from Sell by Deutsche Bank. Price target raised to $110 (2% downside risk) from $105.
    • Gilead Sciences (NASDAQ:GILD) upgraded to Buy from Hold by Jefferies. Price target raised to $91 (16% upside). Morgan Stanley rates it Hold with a price target of $100 (27% upside).
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) upgraded to Outperform from Market Perform with a $66 price target by Oppenheimer.
    • Novo Nordisk (NYSE:NVO) downgraded to Neutral from Overweight by JPMorgan.
    • AbbVie (NYSE:ABBV) downgraded to Neutral from Overweight with a $73 (14% upside) price target by JPMorgan.
    • Cepheid (NASDAQ:CPHD) downgraded to Neutral from Buy by BTIG Research.
    • Tonix Pharmaceuticals (NASDAQ:TNXP) downgraded to Neutral from Buy by Roth Capital.
    • Momenta Pharmaceuticals (NASDAQ:MNTA) downgraded to Sell from Hold with a $6 (48% downside risk) price target by Maxim Group.
    • Biogen (NASDAQ:BIIB) downgraded to Hold from Buy with a $323 (7% upside) price target by Jefferies.
    • Centene (NYSE:CNC) downgraded to Market Perform from Outperform with an $80 (19% upside) price target by Leerink Swann. Wedbush rates it Outperform with an $85 (26% upside) price target.
    | Fri, Sep. 9, 9:59 AM | 12 Comments
  • Mon, Aug. 29, 1:38 AM
    • According to an analysis by the Kaiser Family Foundation, nearly a third of U.S. counties will likely be served by only one insurer that participates in an Affordable Care Act marketplace in 2017, representing an increase from 7% this year.
    • The data underscores the degree to which industry retrenchment from low enrollment and high service costs is curtailing options within the marketplaces.
    • Insurer departures will likely lead to higher prices, analysts have warned.
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    | Mon, Aug. 29, 1:38 AM | 19 Comments
  • Tue, Jul. 26, 7:10 AM
    • Centene (NYSE:CNC) Q2 Results ($M): Total Revenues: 10,897 (+97.9%); Premium and Service: 10,276 (+98.2%).
    • Net Income: 169 (+92.0%); EPS: 0.97 (+34.7%); Non-GAAP EPS: 1.29 (+69.7%); CF Ops (6 mo.): (225) (-157.0%).
    • Health Benefits Ratio: 86.6% (-2.1%).
    • Total Membership: 11,430,800 (+147.8%); Total At-Risk Membership: 8,615,100 (+94.2%).
    • 2016 Guidance: Total Revenues: $39.4B - 40.0B; EPS: $2.65 - 3.00; Non-GAAP EPS: $4.20 - 4.55; Health Benefits Ratio: 87.0 - 87.5%.
    • Shares are up 2% premarket on light volume.
    | Tue, Jul. 26, 7:10 AM | 1 Comment
  • Tue, Jul. 26, 6:02 AM
    • Centene (NYSE:CNC): Q2 EPS of $1.29 beats by $0.20.
    • Revenue of $10.9B (+97.8% Y/Y) beats by $110M.
    • Press Release
    | Tue, Jul. 26, 6:02 AM | 2 Comments
  • Mon, Jul. 25, 5:30 PM
  • Sun, Jul. 10, 9:47 AM
    • WellCare Health Plans (NYSE:WCG) and Centene (NYSE:CNC) have made competing offers for the Medicare Advantage insurance policies - covering about 350K people - that Aetna (NYSE:AET) plans to shed in order to acquire Humana (NYSE:HUM).
    • Aetna presented the divestiture plan on Friday, when meeting with DOJ officials in a bid to address their antitrust concerns.
    | Sun, Jul. 10, 9:47 AM | 2 Comments